CRVO Share Price Performance
US$9.33
-4.00 (-30.01%)
Price US$9.33
Share PriceUS$9.33
CRVO Community Narratives
There are no narratives available yet.
Recent CRVO News & Updates
No updates
CervoMed Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.15
- Gross Margin
- -123.69%
- Net Profit Margin
- -200.58%
- Debt/Equity Ratio
- 0%
CervoMed Inc. Competitors
About CRVO
- Founded
- 2010
- Employees
- 15
- CEO
- WebsiteView website
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a pullback of 2.4% in the Information Technology sector. In the last year, the market is actually up 20%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading